

**REMARKS/ARGUMENTS**

Claims 1-4, 6-10 and 12-15 stand rejected. Claims 5 and 11 are objected to. Claims 1-4, and 7-10 are canceled. Claims 5, 6, and 11-19 are pending. Claims 5, 6, and 12-15 are currently amended. Claims 16-19 are new. No new matter is added by the amendments. Support for the amendments is found in the specification as filed. Reconsideration and allowance are respectfully requested.

Applicants gratefully acknowledge the indication of allowable subject matter in claims 5 and 6.

The Examiner rejected claim 15 under 35 USC § 112, first paragraph, as failing to comply with the enablement requirement. Applicants have amended claim 15 as above. Applicants submit that claim 15 as amended meets the requirements of 35 USC § 112, first paragraph, therefore the rejection is overcome. Applicants request the rejection be withdrawn.

The Examiner rejected claims 1-4, 6-10 and 1-15 for obviousness-type double patenting. In view of the foregoing amendments Applicants submit the rejection is overcome. Applicants request the rejection be withdrawn.

In view of the foregoing, the Applicants submit that all claims are in condition for allowance. Accordingly, both reconsideration of this application and its swift passage to issuance are earnestly solicited. Included herewith is the RCE fee. In the event that there are any fees dues and owing in connection with this matter, please charge the same to our Deposit Account No. 11-0223.

Respectfully submitted,

DATED: July 13, 2007

/Timothy X. Gibson/  
Timothy X. Gibson, Reg. No. 40,618  
Attorney for Applicant(s)

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT 06877  
Tel.: (203) 798-4868